Related Experiment Video

Updated: May 19, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

M Monami1, B Ahrén, I Dicembrini

  • 1Section of Geriatric Cardiology and Medicine, Careggi Teaching Hospital, Florence, Italy. mmonami@libero.it

Diabetes, Obesity & Metabolism
|August 29, 2012
PubMed
Abstract

Insights

Dipeptidyl peptidase-4 inhibitors (DPP4i) significantly reduce cardiovascular events, including myocardial infarction, and all-cause mortality in type 2 diabetes patients. These findings suggest DPP4i offer cardiovascular protection beyond conventional risk factor management.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Preliminary data suggested dipeptidyl peptidase-4 inhibitors (DPP4i) may reduce major adverse cardiovascular events (MACE).
  • Further investigation is warranted to confirm the cardiovascular protective effects of DPP4i.

Purpose of the Study:

  • To conduct a meta-analysis of randomized trials evaluating the effect of DPP4i on cardiovascular outcomes.
  • To verify the potential protective effect of DPP4i against MACE and all-cause mortality.

Main Methods:

  • A comprehensive search of published and unpublished trials comparing DPP4i with placebo or other drugs.
  • Meta-analysis included 70 trials with 41,959 patients, analyzing MACE, myocardial infarction, stroke, and mortality.
  • Random effect models were used to calculate Mantel-Haenszel odds ratios (MH-OR).

Main Results:

  • DPP4i treatment was associated with a reduced risk of MACE (MH-OR 0.71) and myocardial infarction (MH-OR 0.64).
  • A significant reduction in all-cause mortality was observed (MH-OR 0.60).
  • The observed reduction in myocardial infarction risk exceeded predictions based on conventional risk factors.

Conclusions:

  • DPP4i significantly reduce the risk of cardiovascular events, particularly myocardial infarction, and all-cause mortality in type 2 diabetes.
  • The findings suggest DPP4i possess cardiovascular benefits that may involve mechanisms beyond their effects on traditional risk factors.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...